Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2007 / Cilt: 33 - Sayı: 3

Is Re-TUR B necessary for superficial bladder cancer?

Yüzeyel mesane tümörlerinde Re-TUR B gerekli mi?

Pages
272–277
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In high risk bladder tumors, any residual tumors can cause early recurrence and progression, so we believe the residual tumors can be removed and treatment attained through reTUR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: In this study, we aimed to evaluate the rate of residual tumors and/or recurrent tumors and based on those rates to determine whether the treatment options would change or not in patients with superficial bladder tumors who underwent a reTUR (transurethral resection) 4-6 weeks after the initial TUR.
📊
Key Findings & Data:Materials and Methods: This research involves 80 patients who underwent a TUR due to a bladder tumor, and whose pathology results revealed grade 2-3 pTl transitional cancer or grade 2-3 pTa with tumors 3 cm in size or over.
💡
Conclusion & Impact:Conclusion: In high risk bladder tumors, any residual tumors can cause early recurrence and progression, so we believe the residual tumors can be removed and treatment attained through reTUR.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ürolojik cerrahi prosedürler · Transüretral prostat rezeksiyonu · Geriyedönük çalışma

Abstract

Introduction: In this study, we aimed to evaluate the rate of residual tumors and/or recurrent tumors and based on those rates to determine whether the treatment options would change or not in patients with superficial bladder tumors who underwent a reTUR (transurethral resection) 4-6 weeks after the initial TUR. Materials and Methods: This research involves 80 patients who underwent a TUR due to a bladder tumor, and whose pathology results revealed grade 2-3 pTl transitional cancer or grade 2-3 pTa with tumors 3 cm in size or over. None of the patients had any post-resection tumors left. 4-6 weeks later, all the patients underwent a reTUR. New tumor formations were resected wherever seen. Additionally, previous resection surface was resected. The material obtained was sent to the pathology lab in separate tubes. In case of absence of new tumor, the previously resected area was resected only. Following the reTUR, both groups of patients with and without the new tumor formations were administered intracaviter BCG (Bacillus Calmette Guerin) once a week. Results: In 59 out of 80 (73.75%) patients no new tumors were spotted following the reTUR; whereas in 21 patients new tumors were established. Out of these 21 patients, 6 of them (7.5%) had residual tumors (including 1 patient with an up grade), and 11 (13.75%) had recurrent tumors, and 4 (5%) had both residual and recurrent tumors (including 1 patient with an up stage). Compared to the initial tumor pathology, progression was seen in 2 of the patients with tumors after the reTUR. Conclusion: In high risk bladder tumors, any residual tumors can cause early recurrence and progression, so we believe the residual tumors can be removed and treatment attained through reTUR.

Özet

Bu çalışmamızda mesane tümörü nedeniyle transüretral rezeksiyon (TUR) yapılan yüzey el mesane tümörlü hastalarda, 4-6 hafta sonra yapılan reTUR sonucunda geride kalan ve/veya tekrarlayan tümör oranlarını ve bu oranlar ile sonraki tedavi planının değişip değişmediğini saptamayı amaçladık. ; Mesane tümörü nedeniyle TUR yapılan ve patoloji sonuçlan değişici epitel hücreli kanser derece 2-3 pTl olan, veya 3 cm ve üzeri büyüklükte derece 2-3 pTa olan 80 hasta çalışmaya alındı. Bu hastaların hiçbirinde rezeksiyon sonrası rest (görülebilir) tümör kalmamıştı. 4-6 hafta sonra tüm hastalara reTUR yapıldı. Yeni tümöral oluşum varsa rezeke edildi. Ek olarak eski rezeksiyon bölgesi rezeke edildi. Elde edilen gereçler ayrı biyopsi şişelerine konarak patolojiye gönderildi. Yeni tümöral oluşum yoksa sadece eski rezeksiyon bölgesi rezeke edildi. reTUR sonucunda tümör saptanan veya saptanmayan hastalara 6 hafta boyunca intrakaviter BCG (Bacillus Calmette Guerin) haftada bir kez uygulandı. 80 hastanın 59 (%73.75)'unda reTUR sonucunda tümöral oluşuma rastlanmadı. 21 (%26.25) hastada reTUR sonucunda tümör saptandı. Bu 21 hastanın 6'smda (%7.5) artık tümör (1 hasta up grade ), 11'inde (%13.75) tekrarlayan tümör, 4'ünde (%5) hem artık hem de tekrarlayan tümör (1 hasta up stage) saptandı. reTUR'da tümör saptanan 2 hastada ilk tümör patolojisine göre progresyon geliştiği görüldü. Yüksek riskli mesane tümörlerinde, erken nüks ve progresyona sebep olabileceğinden, kalan artık tümörün reTUR ile uzaklaştırılması sağlanabilir kanaatindeyiz.

🔖

Cite This Article

KARSLI, U., ATALAY, A. H., ÜNLÜER, E., TOKTAŞ, G., KOCAASLAN, R., DEMİRAY, M. (2007). Is Re-TUR B necessary for superficial bladder cancer?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 33 - Sayı: 3, 272–277. https://ajindex.com/articles/328296

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Silverberg E, Boring CC, Squires TS: Cancer statistics. Cancer; 40: 9-4, 1990
  2. Torti FM, Lum BL: Superficial bladder cancer, risk of the recurrence and potential role for interferdn therapy. Cancer; 59: 613-616, 1987., 3- Pade-Wilson TS, Bernard RJ: Total cystectomy for bladder tumors. Br. J. Urol; 43: 16-24, 1971
  3. Utz DC, Hanash KA, Farrw GM: The plight of the patient with carcinoma in situ of the bladder. J. Urol; 103: 160-66, 1970
  4. Soloway MS, et al: Superficial bladder cancer. Diagnosis, surveillance and treatment. Journal of Cellular Biochemistry, Supplement; 161: 120-127, 1992
  5. Glashan RW: A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder. J Urol; 144: 658, 1990
  6. Haaff ED, Dresner SM, Ratliff TL, et al: Two courses of intravesical BCG for transitional carcinoma of the bladder. J. Urol; 136: 820, 1986
  7. Torti FM, Shortliffe LD, Williams RD, et al: Alpha interferon in superficial bladder cancer: A Northern California Oncology Group Study. J. Clin. Oncol; 6: 476, 1988
  8. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W: A second-look TUR in Tl transitional cell carcinoma: Why? Eur Urol; 45: 539, 2004
  9. Zurkirchen MA, Sulser T, Gaspert A, Hauri D: Second transurethral resection of superficial transitional cell carcinoma of the bladder: A must even for experienced urologists. Urol Int; 72: 99, 2004
  10. Klan R, Loy V, Huland H: Residual tumor dissoyered in routine second transurethral resection in patients with stage Tl transitional cell carcinoma of the bladder. J. Urol; 146: 316, 1991
  11. Harry W, Herr HW: The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol; 162: 74,1999. 13-Szabo V, Szucs M, Romics I: The role of repeated transurethral resection in the treatment of bladder tumor. Magy Oncol; 44: 236,2000
  12. Ojea Calvo A, Nunez Lopez A, Alonse Rodrigo A, et al: Value of second transurethral resection in the assessment and treatment of patients with bladder tumor. Actas. Urol.Esp; 25: 182,2001
  13. Dalbagni G, Herr HW, Reuter VE: Impact of a second transurethral resection on the staging of Tl bladder cancer. Urology; 60: 822, 2002.